Amitech Therapeutic Solutions

Amitech Therapeutic Solutions is an Israeli biotechnology company focused on the development of a proprietary platform for the targeted delivery of RNA-based therapeutics. Founded by Professor Dan Peer, a pioneer in nanomedicine, the company leverages a modular lipid nanoparticle (LNP) technology known as ASSET (Anchored Secondary scFv Enabling Targeting). This platform allows for the rapid customization of LNPs to target specific cell populations, such as immune cells or tumor cells, by attaching targeting antibodies. The company's primary goal is to enable precision medicine by delivering genetic payloads like mRNA and siRNA directly to the site of disease, thereby increasing efficacy and reducing side effects. Amitech's technology has broad potential applications across oncology, inflammatory diseases, and rare genetic disorders.